Loading news...
AUSTIN, Texas, Feb. 27, 2026 (GLOBE NEWSWIRE) -- IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “AI Service Robotics Market Accelerates as Platforms Move from Prototype to Revenue Deployment,” featuring Nightfood Holdings Inc. (OTCQB:NGTF).
AUSTIN, Texas, Feb. 23, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A,” featuring Oncotelic Therapeutics Inc. (OTCQB: OTLC). To hear the NetworkNewsAudio version, visit https://nnw.fm/hsKrq To read the original editorial, visit https://nnw.fm/IA5ih Platforms supported by existing human data also carry valuation advantages.
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- via IBN -- NetworkNewsAudio announces the Audio Press Release (APR) titled “Closing the Intent-to-Execution Gap May Define Next Wave of AI Investment,” featuring Wearable Devices Ltd. (NASDAQ: WLDS).
Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose level Patient experienced only Grade 1 adverse events Represents second patient with PR to harbor PPP2R1A mutation, supporting mechanistic thesis of targeting WEE1 for this patient population Emerging clinical proof of concept responses without class-limiting toxicity to date support Aprea's development strategy of differentiated WEE1 inhibition with an improved therapeutic index DOYLESTOWN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced additional preliminary data from the ongoing Phase 1 ACESOT-1051 trial evaluating its investigational WEE1 kinase inhibitor APR-1051.
Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051 Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051
Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patient The unconfirmed partial response (uPR) that was observed in the first scan has been achieved at the 150 mg dose, with 220 mg cohort currently enrolling in the ACESOT-1051 Potential dose-response trend observed with increasing single-agent activity across the 70 mg, 100 mg, and 150 mg cohorts Data provide early clinical proof-of-concept for single-agent APR-1051 in patients with advanced solid tumors DOYLESTOWN, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced the first unconfirmed partial response (uPR) observed in a patient enrolled in its ongoing Phase 1 ACESOT-1051 dose-escalation study (A Multi-Center Evaluation of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors).
Swapping 0% APR notes for 7% APR notes just to get three extra years before debt maturity is not a good look for a company that regularly loses money. Beyond Meat's sales are declining across the board as the plant-based meat industry continues to fade.
Automotive Properties Real Estate Investment Trust ( APR.UN:CA ) Q3 2025 Earnings Call November 14, 2025 9:00 AM EST Company Participants Milton Lamb - President, CEO & Director Andrew Kalra - CFO & Corporate Secretary Conference Call Participants Jonathan Kelcher - TD Cowen, Research Division J. Chen Zemin Liu - Desjardins Securities Inc., Research Division Giuliano Thornhill - National Bank Financial, Inc., Research Division Sairam Srinivas - Cormark Securities Inc., Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Automotive Properties REIT's 2025 Third Quarter Results Conference Call and Webcast.
This article has been disseminated on behalf of ESGold Corp . and may include a paid advertisement.
This article has been disseminated on behalf of LaFleur Minerals and may include paid advertising.
AUSTIN, Texas, Oct. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) title “Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology,” featuring Oncotelic Therapeutics Inc. (OTCQB: OTLC).
AUSTIN, Texas, Oct. 27, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Investors Eye Next-Gen 3D AI-Imaging Technologies in Growing $9 Billion Market,” featuring Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF). To hear the NetworkNewsAudio version, visit https://nnw.fm/m5BU6 To read the original editorial, visit https://nnw.fm/7yoEs This integration of AI with volumetric imaging technologies, such as tomosynthesis, MRI and dedicated breast CT, signals a broader shift toward intelligent diagnostics capable of generating and interpreting 3D data simultaneously.
DOYLESTOWN, Pa., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on the ongoing Phase 1 ACESOT-1051 (A Multi-Center Evaluation of WEE1 Inhibitor in Patients with Advanced Solid Tumors, APR-1051) study. The latest results show that, at the 100 mg APR-1051 dose level, 3 out of 4 patients achieved stable disease, as measured using RECIST v1.1 criteria.
AUSTIN, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Gold Surges Past $4,200 as Investors Flock to Producers with Cash Flow,”featuring ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF).
AUSTIN, Texas, Oct. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “When the Dollar Blinks, Real Assets Take Center Stage,” featuring ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF).